Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impacts of IPSS-m and conditioning intensity in allogeneic hematopoietic cell transplant for patients with myelodysplasia neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHongru ChenMHMinli HuCZChupeng Zhang

Discussion

Loading...

Member takes

Overview

Retrospective study identifies risk factors that influence overall survival in myelodysplastic syndrome patients undergoing transplant.

Key Points

  • Overall survival 77.8% with specific risk factors affecting outcomes in myelodysplastic syndrome patients.
  • Key metrics include non-relapse mortality at 11.4% and incidence of chronic graft versus host disease at 21.4%.
  • Retrospective multicenter analysis across myelodysplastic syndrome patients who underwent allogeneic transplant.
  • Identifies critical implications for conditioning intensity and risk factors in optimizing patient outcomes.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d75ahttps://doi.org/10.1182/blood-2025-1062
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes2025
  2. 2Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes2025 · 1 citations
  3. 3Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification2025
  4. 4Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT2025 · 2 citations
  5. 5Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review2025